Evidence map›Paper›PMID 42016713›Full record

ReviewJournal of orthopaedic translation2026

Protective effects of irisin in sarcopenia: a promising treatment.

Yixiao Chen, Guoqing Li, Feng Gao, Ruijiang Li, Minghui Yang, Yufeng Ge, Xinbao Wu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yixiao ChenDepartment of Traumatic Orthopaedics, Beijing Jishuitan Hospital, Capital Medical University, Beijing, 100035, China.
Guoqing LiDepartment of Orthopaedics, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
Feng GaoDepartment of Traumatic Orthopaedics, Beijing Jishuitan Hospital, Capital Medical University, Beijing, 100035, China.
Ruijiang LiDepartment of Traumatic Orthopaedics, Beijing Jishuitan Hospital, Capital Medical University, Beijing, 100035, China.
Minghui YangDepartment of Traumatic Orthopaedics, Beijing Jishuitan Hospital, Capital Medical University, Beijing, 100035, China.
Yufeng GeDepartment of Traumatic Orthopaedics, Beijing Jishuitan Hospital, Capital Medical University, Beijing, 100035, China.
Xinbao WuDepartment of Traumatic Orthopaedics, Beijing Jishuitan Hospital, Capital Medical University, Beijing, 100035, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcopenia is an age-related progressive muscle degeneration condition characterized by loss of muscle mass, muscle strength, and poor physical function. Its prevalence and mortality rates continue to rise with advancing age, significantly impairing patients' quality of life. The pathogenesis of sarcopenia involves multiple pathophysiological processes, including imbalanced protein catabolism, cell death, mitochondrial dysfunction, and various cellular signaling pathways. Therefore, it is crucial to identify potential therapeutic targets and treatments for sarcopenia. As an exercise-induced myokine, irisin has shown great potential in maintaining skeletal muscle health. In this review, we focus on the relationship between irisin and sarcopenia, delving into existing research to elucidate irisin's mechanisms of action in sarcopenia-including its effects on protein catabolism, cell death, mitochondrial dysfunction, cellular signaling, and muscle cell proliferation and differentiation. We provide insights into irisin as a therapeutic intervention for sarcopenia and provide essential evidence to support its clinical application in sarcopenia treatment.

Indexed as

Cell deathIrisinProtein metabolic balanceSarcopeniaSignaling pathwayTreatment

Identifiers

PMID42016713
PMCPMC13092673

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.